Calando Finds Partner for Non-RNAi Technology, Has No Plans to Restart In-House RNAi Programs

While the deal provides Calando parent firm Arrowhead Research with a measure of much-needed financial relief, the company indicated that it still has no plans to restart on its own any of its RNAi programs, which were halted due to financial constraints and have been on the block for some time.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.